Marinomed Biotech AG
MARI.VI · VIE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | €4,747 | €9,184 | €11,276 | €11,628 |
| % Growth | -48.3% | -18.6% | -3% | – |
| Cost of Goods Sold | €9,015 | €8,041 | €9,135 | €10,204 |
| Gross Profit | -€4,268 | €1,143 | €2,141 | €1,424 |
| % Margin | -89.9% | 12.4% | 19% | 12.2% |
| R&D Expenses | €255 | €0 | €6,906 | €7,504 |
| G&A Expenses | €0 | €1,020 | €1,393 | €1,056 |
| SG&A Expenses | €2,527 | €1,267 | €1,692 | €1,452 |
| Sales & Mktg Exp. | €0 | €247 | €299 | €396 |
| Other Operating Expenses | -€28 | €5,005 | -€1,543 | -€3,388 |
| Operating Expenses | €2,754 | €6,272 | €7,054 | €5,569 |
| Operating Income | -€7,022 | -€5,129 | -€5,751 | -€4,145 |
| % Margin | -147.9% | -55.9% | -51% | -35.6% |
| Other Income/Exp. Net | -€8,494 | -€1,662 | -€640 | -€1,550 |
| Pre-Tax Income | -€15,515 | -€6,791 | -€6,391 | -€5,694 |
| Tax Expense | -€99 | €4 | €7 | €197 |
| Net Income | -€15,416 | -€6,795 | -€6,398 | -€5,891 |
| % Margin | -324.8% | -74% | -56.7% | -50.7% |
| EPS | -8.67 | -4.48 | -4.27 | -3.99 |
| % Growth | -93.5% | -4.9% | -7% | – |
| EPS Diluted | -8.67 | -4.5 | -4.27 | -3.99 |
| Weighted Avg Shares Out | 1,778 | 1,518 | 1,499 | 1,476 |
| Weighted Avg Shares Out Dil | 1,778 | 1,518 | 1,499 | 1,476 |
| Supplemental Information | – | – | – | – |
| Interest Income | €24 | €17 | €0 | -€60 |
| Interest Expense | €7,922 | €1,382 | €2,508 | €1,509 |
| Depreciation & Amortization | €413 | €678 | €670 | €609 |
| EBITDA | -€7,181 | -€3,623 | -€3,213 | -€3,576 |
| % Margin | -151.3% | -39.4% | -28.5% | -30.8% |